Clinical Approach and Combination Therapy
Start with the big picture
For HFrEF, the source describes initial guideline-directed therapy as combining an ACE inhibitor, ARB, or ARNI with a β-blocker and an MRA, unless contraindicated. SGLT2 inhibitors are also part of contemporary therapy, regardless of diabetes status. Treatment is individualized: β-blockers are started when the patient is euvolemic and titrated gradually, while MRAs require potassium and kidney-function monitoring. Diuretics help relieve congestion but are not presented as mortality-reducing therapy. Persistent symptoms or specific clinical features may prompt consideration of additional medicines, while acute hypoperfusion may require short-term support. The broader lesson connects these choices to treatment goals and covers supportive care, reassessment, and therapy across different heart-failure contexts.
What you'll learn
- Describe the core combination of guideline-directed therapy for HFrEF.
- Distinguish medicines aimed at survival benefits from those used mainly for symptom relief.
- Identify key considerations for β-blocker initiation and MRA monitoring.
- Recognize situations in which adjunctive therapies may be considered.
- Name medication groups the source identifies as potentially harmful in heart failure.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
